NNVC•NanoViricides said its Phase IIA trial of NV-387 Oral Gummies for Ebola is progressing well and is expected to advance to Phase IIB after completion. Enrollment began Sept. 23, 2026, in the Democratic Republic of Congo.
NanoViricides said its Phase IIA trial of NV-387 Oral Gummies for Ebola is progressing well, with advancement to Phase IIB expected after completion. Enrollment began Sept. 23, 2026, in the Democratic Republic of Congo, and the study evaluates dosing based on disease severity. The treatment targets Ebola Bundibugyo, for which no treatment or vaccine is currently approved. NV-387 Oral Gummies is also in a Phase II trial for mpox in the Democratic Republic of Congo.
